Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04072809 · ClinicalTrials.gov registry record

Dissecting the Genetics of Fetal Alcohol Spectrum Disorders

A clinical trial, sponsored by Indiana University.

Completed
Registry status
751
Enrollment target

NCT04072809: Completed study, sponsored by Indiana University.

NCT04072809 is a clinical trial that has completed, run by Indiana University. The registered enrollment target is 751 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04072809 has completed, sponsored by Indiana University.

COMPLETED
Registry status
751 participants
Enrollment target

Study Summary

The purpose of this study is to help scientists understand why some people who were exposed to alcohol in the womb have special facial features but other people do not. This study will test if genetics (or DNA) explains these differences. We hope this will help improve treatments and interventions for people with fetal alcohol spectrum disorders (FASD). Participants in this study (or their parents or legal guardians) will be asked to: * Answer some questions about themselves. These questions ask about their demographic background (such as gender, race, ethnicity, income, and education), their health history, and their mother's health during her pregnancy with them (if that information is known). * Speak with study staff briefly by phone or video chat to confirm enrollment in the study and ask any questions they have. * Take photographs of their face. * Provide a saliva sample for genetic research. Participants can complete the study at home from anywhere in the world. The questions can be answered online, over the phone, or on paper. Adopted families are welcome to enroll. The study pays for all shipping costs.

Primary Outcome

Facial Risk Score Each participant's facial images will be evaluated and a Facial Risk Score will be assigned to each individual. This risk score is relative to all individuals participating in the study, and therefore will be updated at the end of each year. Final scores will be completed at the end of the study. The risk score is computer-based, with high scores indicating increased dysmorphology and low scores indicating decreased dysmorphology.

Interventions

  • OTHER No intervention

Trial Details

FieldValue
Enrollment Target 751 participants
Start Date 2018-07-06
Est. Completion 2023-05-01
Indiana University

890 total trials

What the finished NCT04072809 record still lists

NCT04072809 is an observational study that tracks outcomes without assigning an intervention. The registered 751 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.

NCT04072809 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04072809 about?

NCT04072809 is a clinical study titled "Dissecting the Genetics of Fetal Alcohol Spectrum Disorders". The purpose of this study is to help scientists understand why some people who were exposed to alcohol in the womb have special facial features but other people do not. This study will test if genetics (or DNA) explains these differences. We hope this will help improve treatments and interventions f...

What is the current status of trial NCT04072809?

This trial is currently completed. The enrollment target is 751 participants. The study started on 2018-07-06. Estimated completion is 2023-05-01.

What interventions are being tested in trial NCT04072809?

The interventions under investigation include: No intervention (OTHER).

Who is sponsoring clinical trial NCT04072809?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06559306 · 752 participants · Phase 3

    Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  • NCT02048332 · 750 participants · Phase 1

    Donor-Derived Viral Specific T-cells (VSTs)

  • NCT02087852 · 750 participants

    Kidney Cancer DNA Registry

  • NCT02532452 · 750 participants · Phase 2

    Third Party Viral Specific T-cells (VSTs)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04072809, the US trial registry maintained by the National Library of Medicine. NCT04072809 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.